After collaborating with Mr. Franklin in his classroom learning environment during this time, you recognize that he has been expressing his confusion regarding special education and the students’ needs. You have decided to create a user-friendly guide that has relevant resources, definitions, examples, and family-based support information specific to students with exceptionalities that can be shared easily with colleagues.
Prior to beginning work on this final paper:
Read Chapter 7 in the textReview Section 2.2, pages 34 and 37 in the textReview the webpage Ethical Principles and Professional Practice Standards for Special Educators (Links to an external site.)Review the Code of Ethics: Preamble—Statement of Purpose (Links to an external site.) .Review Educational Rights and IEPs (Links to an external site.)Review the course learning outcomes.Review the weekly learning outcomes from Weeks 1 through 5.Consider looking back through the Instructor Guidance lessons from Weeks 1 through 5.Locate and review the assignment artifacts from Weeks 1 through 5.Thoroughly read the final paper instructions.
As you navigate this final paper, consider how you will apply the course learning outcomes to your chosen path or learning environment in the field of education.
Upon successful completion of this course, students will be able to:
Explain how federal legislation governs special education protocol in public schools or other learning environments.Analyze the characteristics and learning differences between eligibility categories under IDEA for students with exceptionalities.Summarize evidence-based practices that address the academic, as well as social/emotional and behavioral needs of students with exceptionalities.Illustrate the key points of the relevant ethical principles and legislation guiding professionals working with students with exceptionalities.Describe educational supports, services, and support personnel for students with exceptionalities.
icially recurrent melanoma; chest wall recurrence of breast cancer; or recurrent cervical lymph nodes from head and neck cancer” (Excellus). Although this insurance approves of certain types of hyperthermia, others are only considered investigational to them. The treatments that are considered investigational are interstitial hyperthermia, regional hyperthermia, regional perfusion hyperthermia, and whole-body hyperthermia. The reason the Excellus BlueCross BlueShield and the FDA have not approved other types of hyperthermia treatment is because studies do not have enough patients, do not have a standard technique, are not random or controlled, and do not have long term results. Currently the Food and Drug Administration (FDA) has approved hyperthermia in the treatment of solid surface and subsurface malignant tumors that are recurrent or progressive despite regular treatment (Excellus). Medicare approves hyperthermia treatment when used with radiation for primary or metastatic cutaneous or subcutaneous superficial malignancies and it is not covered when used alone or with chemotherapy (Center for Medicare and Medicaid Services). Although not all treatments are FDA approved, University of California San Francisco uses “multi-modality hyperthermia” meaning that they customize the treatment to each patient’s cancer, including combining chemotherapy and hyperthermia (UCSF). Cost of treatment is something that is very important to cancer treatment, as if something is too expensive, it limits the availability of treatment. Based on research on line, there are no current prices for the cost of hyperthermia treatment, but we can infer from other countries and the past on what the cost might be like now. Back in 1994 a “hyperthermia project” was done at the University of Turin in Italy. When the cost of treatment is converted to USD, the cost per treatment was around $2,676 but that was back in 1994(Gabriele 1994). When accounting for inflation, the cost per treatment would now be $68,038.52. Prognosis When hyperthermia therapy is used in conjunction with radiation therapy, in the t>GET ANSWER